The tepezza lawsuit 2026 docket stands at a critical crossroads, with more than 270 claimants waiting, bellwether trial dates vacated, and global settlement speculation intensifying. The case has already seen dramatic procedural swings: trial dates that moved multiple times, a full deadline vacation that sparked widespread resolution speculation, and a Daubert ruling that kept plaintiffs’ most critical expert standing. Now, with Amgen carrying a $27.8 billion acquisition’s worth of liability and Judge Durkin ordering quarterly settlement negotiations throughout 2025 and 2026, all eyes are on whether this litigation resolves before a single juror is ever seated.
What Is the Tepezza Lawsuit? Background on the Drug and the Harm
Tepezza (teprotumumab-trbw) received FDA approval in January 2020 as the first-ever drug specifically indicated for thyroid eye disease, a condition that causes painful inflammation and protrusion of the eyes in patients with thyroid disorders. The approval was widely celebrated as a breakthrough — but within years of its commercial launch, reports began emerging that patients were developing significant, and in many cases irreversible, hearing loss and tinnitus after completing their infusion courses.
The biological mechanism at issue involves Tepezza’s blockade of the IGF-1R receptor. Researchers and plaintiffs’ experts contend that this same receptor pathway plays a critical structural role in the cochlea — the inner ear’s sound-processing organ — and that blocking it may damage or destroy the delicate hair cells responsible for converting sound waves into neural signals. Once those hair cells are lost, they do not regenerate. For patients who underwent multiple Tepezza infusions, the alleged result is permanent, life-altering hearing impairment.
Despite these emerging signals, the FDA did not require an updated warning label addressing hearing loss until July 2023 — more than three years after approval. That updated label now requires healthcare providers to monitor patients’ hearing during treatment. Plaintiffs in the tepezza lawsuit 2026 allege that Horizon Therapeutics, Tepezza’s original manufacturer, was aware of the hearing risk long before that label update and failed to warn prescribing physicians and patients in a timely manner. To understand how drug injury compensation is typically valued, reviewing a medical malpractice calculator can provide useful context for defective pharmaceutical claims.
MDL 3079: How the Federal Case Is Structured
Because Tepezza hearing loss claims were filed across multiple federal districts, the U.S. federal court system consolidated them into a single Multidistrict Litigation proceeding — MDL 3079 — centralized in the Northern District of Illinois before U.S. District Judge Thomas Durkin. MDL consolidation is the standard procedural mechanism for mass tort cases involving many plaintiffs sharing common factual questions against a single manufacturer.
Under the MDL structure, pretrial discovery, expert challenges, and bellwether trials are handled centrally. As of early 2026, MDL 3079 has grown to approximately 270 filed cases, up from the 260-plus figure cited in earlier reporting. Judge Durkin has ordered the parties to meet quarterly for settlement negotiations throughout 2025 and 2026 — a directive that signals the court’s strong preference for a negotiated resolution. If the parties cannot reach a global settlement, Judge Durkin retains the authority to remand individual cases back to their home districts for trial.
The MDL’s bellwether process is designed to give both sides real-world data points on how juries evaluate the core liability and damages questions. However, with all bellwether trial dates currently vacated as of late 2025, the litigation has entered a posture that most mass tort observers associate with advanced — if not imminent — settlement discussions.
Amgen’s $27.8 Billion Acquisition and What It Means for Defendants
When Amgen completed its $27.8 billion acquisition of Horizon Therapeutics in October 2023, it inherited not only Tepezza’s blockbuster commercial revenue but also the full weight of the MDL 3079 liability. For plaintiffs, the acquisition is significant: Amgen is one of the world’s largest biotechnology companies, with financial resources capable of funding a substantial global settlement without existential risk to the enterprise.
For Amgen’s legal team, the calculus is more nuanced. Tepezza remains a commercially important asset, generating significant annual revenue for thyroid eye disease patients who depend on it. Any settlement must be structured in a way that resolves historical claims without creating a template that invites future litigation or undermines the drug’s ongoing commercial viability. Amgen has not publicly confirmed settlement negotiations, but the combination of vacated trial dates and court-ordered quarterly mediation sessions in 2026 has led most litigation observers to conclude that resolution discussions are well underway.
The Dramatic Timeline: From Vacated Deadlines to Settlement Talks in 2026
The procedural history of MDL 3079 reflects the complexity and high stakes of the litigation.
Bellwether Selection and the Original Schedule
In the early phases of MDL 3079, Judge Durkin oversaw the selection of bellwether plaintiffs — a representative pool of cases chosen to go to trial first. The selection process involved extensive plaintiff fact sheets, medical record review, and negotiation between the parties over which cases best represented the broader claims. Original trial schedules were set with the expectation that the first bellwether would reach a jury within a defined pretrial timeline.
October 2025: All Deadlines Vacated
In a development that immediately drew attention across the mass tort litigation community, Judge Durkin vacated all pending Tepezza trial deadlines in October 2025. Courts presiding over MDL proceedings do not typically vacate fully constructed trial schedules without cause — and the cause most commonly associated with such a move is meaningful progress toward a global settlement. While neither Amgen nor plaintiffs’ leadership formally confirmed that a deal was imminent, the deadline vacation combined with the court’s standing order for quarterly settlement conferences created a strong inference that the parties were in serious resolution discussions.
The Reset: Where Things Stand in 2026
As of 2026, no new bellwether trial dates have been set. The suspension of the trial calendar, combined with Judge Durkin’s mandate for ongoing quarterly negotiations, has placed MDL 3079 in a holding pattern that is characteristic of litigation approaching a comprehensive resolution. Plaintiffs’ attorneys and Amgen’s defense team continue to work through the framework of a potential settlement, with causation evidence and individual injury severity serving as the primary variables in valuing individual claims. Whether a global announcement emerges in 2026 or the parties ultimately return to a trial schedule remains the central question of the litigation.
The Daubert Ruling: Why Plaintiffs’ Expert Survives
One of the most consequential pretrial developments in MDL 3079 was Judge Durkin’s Daubert ruling, which denied Amgen’s motion to exclude plaintiffs’ key causation expert. In pharmaceutical mass tort litigation, Daubert challenges — named for the Supreme Court standard governing the admissibility of expert scientific testimony — are often the single most important pretrial battleground. If a defendant successfully excludes plaintiffs’ causation expert, the claims frequently collapse because plaintiffs cannot establish the scientific link between the drug and the alleged injury.
In the Tepezza MDL, Amgen argued that plaintiffs’ expert’s opinion linking teprotumumab to cochlear damage was not sufficiently grounded in reliable scientific methodology. Judge Durkin disagreed, finding that the expert’s methodology — drawing on animal studies, pharmacological mechanism analysis, and adverse event data — met the threshold for admissibility. The ruling does not guarantee plaintiffs will prevail at trial, but it ensures they will have the opportunity to present their core scientific theory to a jury, a critical prerequisite for any litigation leverage in settlement negotiations.
The survival of the causation expert also meaningfully affects individual case valuations. With a credible, court-vetted expert in place, plaintiffs’ attorneys can negotiate from a position of demonstrated scientific credibility rather than theoretical liability.
Settlement Talks and What Individual Cases May Be Worth
Although no global Tepezza settlement has been officially confirmed as of 2026, the litigation’s current posture — vacated trial dates, court-ordered quarterly negotiations, a surviving causation expert, and a well-capitalized defendant — creates the conditions for a substantial resolution. Legal analysts tracking the MDL estimate that individual Tepezza settlements could range from approximately $75,000 to $200,000 or more per claimant, depending on the severity of the hearing injury and the strength of individual causation evidence.
Cases involving profound or total hearing loss, documented audiological testing showing pre- and post-Tepezza decline, and clear medical records linking the infusion schedule to onset of symptoms are likely to command values at the higher end of that range. Cases involving mild or disputed tinnitus, or those with complicating causation factors such as prior hearing conditions, will likely resolve at lower values or face greater scrutiny in the claims administration process.
The July 2023 FDA label update requiring hearing monitoring during treatment is a double-edged sword in settlement negotiations. For plaintiffs treated before July 2023, it reinforces the argument that they were not warned of a known risk. For plaintiffs treated after the label change, defendants may argue that updated warnings were in place and that prescribers had an obligation to monitor and respond to hearing changes — potentially shifting some responsibility away from Amgen.
The quarterly settlement conferences ordered by Judge Durkin throughout 2025 and 2026 are designed to keep both sides at the table and maintain momentum toward resolution. In large pharmaceutical MDLs, this kind of structured judicial oversight of settlement discussions frequently accelerates the timeline toward a global deal.
Key Litigation Statistics at a Glance
- MDL case count: Approximately 270 as of early 2026
- Presiding judge: U.S. District Judge Thomas Durkin, Northern District of Illinois
- Defendant: Amgen Inc. (acquired Horizon Therapeutics in October 2023 for $27.8 billion)
- Primary alleged injury: Permanent hearing loss and tinnitus following Tepezza infusions
- FDA label update: July 2023 — now requires monitoring of patients’ hearing during treatment
- Daubert ruling: Plaintiffs’ causation expert survived challenge; ruling upheld admissibility
- Bellwether trial status: All trial dates vacated as of October 2025; no new dates set as of 2026
- Estimated individual settlement range: $75,000–$200,000+ depending on injury severity and causation evidence
- Settlement conference schedule: Quarterly meetings ordered by Judge Durkin throughout 2025–2026
What Happens After the Bellwether Trials?
In a typical MDL trajectory, bellwether trials produce verdicts that serve as data points for global settlement negotiations. A plaintiff verdict — especially a large one — accelerates defendant willingness to settle. A defense verdict emboldens the defendant to offer less or push more cases to trial. In the Tepezza MDL, however, the vacation of all trial dates means that the traditional bellwether-to-settlement pipeline has been at least temporarily bypassed.
If the parties reach a global settlement agreement in 2026, it will likely involve a claims administration process through which individual plaintiffs submit medical documentation, audiological records, and other evidence to establish eligibility and determine their individual compensation tier. A special master or claims administrator would oversee the process, with plaintiffs’ leadership counsel negotiating the allocation grid on behalf of the claimant population.
If settlement talks break down and the court resets a trial schedule, the first bellwether verdict will become the most closely watched data point in pharmaceutical litigation for the remainder of 2026 and into 2027. Either outcome — resolution or trial — will have significant implications for the approximately 270 claimants currently in the MDL and for the broader population of Tepezza patients who may still be deciding whether to file.
Frequently Asked Questions About the Tepezza Lawsuit 2026
What injuries are at the center of the tepezza lawsuit 2026?
The primary injuries alleged in the Tepezza lawsuit are permanent sensorineural hearing loss and tinnitus — a persistent ringing or buzzing in the ears. Plaintiffs allege that Tepezza’s mechanism of action, specifically its blockade of the IGF-1R receptor, damages the cochlear hair cells responsible for hearing. Because these cells do not regenerate, the hearing loss alleged in most cases is described as permanent and progressive. The FDA’s July 2023 label update, which now requires healthcare providers to monitor patients’ hearing during Tepezza treatment, is cited by plaintiffs as a belated acknowledgment of a risk that Horizon Therapeutics allegedly knew about far earlier.
When is the first Tepezza bellwether trial scheduled?
As of 2026, there is no active bellwether trial date on the calendar. Judge Durkin vacated all Tepezza trial deadlines in October 2025. The vacation of trial dates, combined with court-ordered quarterly settlement negotiations, strongly suggests the parties are engaged in serious resolution discussions. If those discussions fail to produce a global settlement, the court is expected to reset a trial schedule, but no new dates have been announced as of the time of this writing.
Why did the court vacate all Tepezza trial deadlines in October 2025?
Courts overseeing complex MDL proceedings rarely vacate fully constructed trial schedules without a compelling reason. In the context of MDL 3079, the October 2025 deadline vacation is widely interpreted by mass tort practitioners as a signal that the parties are engaged in advanced settlement discussions. Judge Durkin’s standing order requiring quarterly settlement conferences throughout 2025 and 2026 reinforces this interpretation. Neither Amgen nor plaintiffs’ leadership has officially confirmed a settlement agreement, but the procedural posture of the case is consistent with litigation approaching a negotiated global resolution.
How much money could Tepezza plaintiffs receive in a settlement?
Based on current litigation analysis, individual Tepezza settlements are estimated to range from approximately $75,000 to $200,000 or more per claimant, depending on the nature and severity of the hearing injury and the strength of the causation evidence in each individual case. Plaintiffs with documented profound hearing loss, clear audiological evidence of pre- and post-Tepezza decline, and treatment histories that predate the July 2023 FDA label update are likely to receive higher compensation. Cases involving less severe symptoms or disputed causation may settle at lower values. No official settlement amounts have been confirmed as of 2026.
Who is now responsible for defending the Tepezza lawsuits?
Amgen Inc. is the primary defendant in MDL 3079. Amgen acquired Horizon Therapeutics — Tepezza’s original developer and manufacturer — in October 2023 for approximately $27.8 billion. As part of that acquisition, Amgen assumed responsibility for all pending and future Tepezza-related litigation. Amgen is one of the world’s largest biotechnology companies, and its financial resources are widely viewed as sufficient to fund a substantial global settlement. The company has not publicly commented on the specific terms or status of any settlement discussions in the Tepezza MDL.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.